| Literature DB >> 25295080 |
Jian-Feng Liu1, Li-Rong Zhao2, Lai-Jin Lu1, Lei Chen1, Zhi-Gang Liu1, Xu Gong1, Bin Liu1.
Abstract
Melanomas affect the foot and ankle region and are associated with a poor prognosis. The aim of the current study was to evaluate the functional and oncological outcomes of salvage surgery using cutaneous flaps for soft tissue reconstruction of the foot and ankle following the extended resection of a melanoma. A retrospective review was conducted to evaluate patients who presented with foot melanoma and underwent salvage surgery and defect reconstruction using three types of cutaneous flap (group S) or amputation (group A) between January 1999 and December 2010 at the First Hospital of Jilin University (Changchun, China). The postoperative mortality, surgical complications, functional outcomes and oncological outcomes were evaluated. Of the 21 patients, 11 were enrolled into group S and 10 were enrolled into group A. The median follow-up time of the patients was 58 months (range, 6-92 months). In group S, a reverse sural neurocutaneous island flap was used in six patients to perform the foot reconstruction, medial plantar flaps were used in four patients and lateral malleolus flaps were used in one patient. All 11 cutaneous flaps survived and provided satisfactory coverage. Only one cutaneous flap showed partial necrosis and required treatment comprising of debridement and regular changes to the wound dressing. The overall survival rate of patients was 65.0% and patients in the two groups experienced similar oncological outcomes. Salvage surgery with cutaneous flap reconstruction was found to be a reliable option for patients presenting with malignant melanoma of the foot and ankle.Entities:
Keywords: cutaneous flaps; foot and ankle; malignant melanoma; salvage surgery; soft tissue defects
Year: 2014 PMID: 25295080 PMCID: PMC4186625 DOI: 10.3892/ol.2014.2440
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Demographics of the patients in groups S and A.
| A, Group S | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Post surgery | |||||||||
|
| |||||||||
| Patient no. | Gender | Age (years) | Affected foot | Location | Tumor stage | Surgical method | Follow-up (months) | Recurrence/ Metastasis | Patient status |
| 1 | Female | 60 | Right | Lateral plantar foot | I | Extended resection + MPF + skin graft | 48 | No/No | Succumbed to CVD |
| 2 | Female | 49 | Left | Plantar | II | Extended resection + MPF | 25 | No/No | N/A |
| 3 | Male | 63 | Right | Heel | II | Extended resection + RSIF | 6 | Yes/Yes (Ing.) | DOD |
| 4 | Male | 63 | Right | Lateral dorsal foot | I | Extended resection + RSIF | 77 | No/No | AWD |
| 5 | Female | 55 | Left | Plantar | I | Extended resection + MPF | 62 | No/No | AWD |
| 6 | Male | 39 | Right | Heel | II | Tumor resection + RSIF | 13 | Yes/Yes (Ing./Pop.) | DOD |
| 7 | Female | 54 | Right | Lateral malleolus | II | Extended resection + LSMF | 57 | No/No | AWD |
| 8 | Male | 57 | Right | Dorsum of foot | I | Extended resection + RSIF | 62 | No/No | NED |
| 9 | Male | 70 | Left | Heel | III | Tumor resection + RSIF | 8 | No/Yes (Lung) | DOD |
| 10 | Male | 61 | Left | Plantar | II | Extended resection + MPF | 18 | No/No | NED |
| 11 | Female | 50 | Right | Heel | I | Extended resection + RSIF | 13 | No/No | NED |
|
| |||||||||
| B, Group A | |||||||||
|
| |||||||||
| Post surgery | |||||||||
|
| |||||||||
| Patient no. | Gender | Age (years) | Affected foot | Location | Tumor stage | Surgical method | Follow-up (months) | Recurrence/Metastasis | Patient status |
|
| |||||||||
| 12 | Female | 52 | Right | Plantar | I | Leg amputation | 92 | No/No | NED |
| 13 | Male | 55 | Right | Medial dorsal foot | I | Leg amputation | 73 | No/No | NED |
| 14 | Male | 58 | Left | Medial malleolus | II | Skin graft, leg amputation | 22 | Yes/Yes (Ing./Pop.) | DOD |
| 15 | Male | 46 | Left | Toe | I | Toe amputation | 68 | No/No | NED |
| 16 | Female | 45 | Left | Toe | I | Toe amputation | 58 | No/No | NED |
| 17 | Male | 59 | Right | Medial plantar foot | I | Tarsometatarsal amputation | 55 | No/No | NED |
| 18 | Male | 49 | Right | Toe | I | Leg amputation | 10 | No/No | NED |
| 19 | Male | 59 | Left | Toe | III | Toe amputation + ilioinguinal lymph node dissection | 12 | No/Yes (Lung) | DOD |
| 20 | Male | 46 | Left | Second toe | III | Toe amputation | 9 | Yes/No | DOD |
| 21 | Male | 49 | Right | Plantar | II | Leg amputation | 29 | No/No | NED |
This patient was subsequently lost to follow-up.
CVD, cardiovascular disease; N/A, not available; MPF, medial plantar flap; RSIF, reverse sural neurocutaneous island flap; LSMF, lateral supramalleolar flap; AWD, alive with disease; NED, alive with no evidence of disease; DOD, died from disease; Ing., inguinal; Pop., popliteal.
Features of the cutaneous flaps observed in the patients in Group S.
| Patient no. | Type of flap | Size of wound (cm × cm) | Size of flap (cm × cm) | Sensory recovery | Wear-resistant | Short-term complication |
|---|---|---|---|---|---|---|
| 1 | MPF | 4×4 | 6×4 | Yes | Yes | None |
| 2 | MPF | 5×4 | 8×6 | Yes | Yes | None |
| 3 | RSIF | 6×5 | 15×8 | No | No | Edema |
| 4 | RSIF | 11×8 | 25×8 | No | No | None |
| 5 | MPF | 6×5 | 8×7 | No | Yes | None |
| 6 | RSIF | 6×8 | 11×8 | No | Yes | None |
| 7 | LSMF | 4×4 | 8×4 | Yes | Yes | None |
| 8 | RSIF | 5×4 | 12×6 | Yes | Yes | Mild infection |
| 9 | RSIF | 8×9 | 25×10 | Yes | Yes | Mild infection, partial necrosis |
| 10 | MPF | 5×4 | 8×6 | Yes | Yes | None |
| 11 | RSIF | 6×4 | 8×6 | Yes | Yes | Limited range of motion |
MPF, medial plantar flap; RSIF, reverse sural neurocutaneous island flap; LSMF, lateral supramalleolar flap.
Figure 1Images of female patient no. 5, aged 55 years. (A) The patient was diagnosed with a melanoma on the sole of the foot, which was identified by pathological investigation. (B) The black mass was completely removed by surgery. (C) The image was obtained three days following tumor resection and soft tissue reconstruction using a medial plantar flap. (D) Clinical image of the foot demonstrates the healed recipient site 10 days following cutaneous flap placement. The protective sensation remained functional in the affected area.
Figure 2Images of female patient no. 11 (aged 50 years) who was diagnosed with a malignant melanoma on the heel of the right foot. The patient underwent defect reconstruction using a reverse sural neurocutaneous island flap following tumor resection. (A) Preoperative image. (B) The image was obtained 10 days postoperatively and demonstrates that the heel of the foot was successfully restored.